Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Active not recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3Sarcoma 2Plasma cell 2Lymphoid 2Genitourinary 2Breast 2Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1

Conditions

Glioma 3Wilms Tumor 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Neuroectodermal Tumors, Primitive 1Neuroblastoma 1Neoplasms, Neuroepithelial 1Medulloblastoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Hodgkin Disease 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Desmoplastic Small Round Cell Tumor 1

Interventions

Temozolomide 610Radiotherapy 388Bevacizumab 254Magnetic Resonance Spectroscopy 203Cyclophosphamide 177Carboplatin 159Radiosurgery 146Etoposide 132Radiation 121Irinotecan 115Vincristine 114Cisplatin 102Filgrastim 100Specimen Handling 88Nivolumab 87pembrolizumab 82Lomustine 81Topotecan 73Surgical Procedures, Operative 73Doxorubicin 60Melphalan 59Carmustine 57sargramostim 53Radiotherapy, Intensity-Modulated 53Isotretinoin 53Peripheral Blood Stem Cell Transplantation 52Granulocyte Colony-Stimulating Factor 50Erlotinib Hydrochloride 50Everolimus 48Chemotherapy, Adjuvant 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × CLR1404 × CNS × Clear all
NCT03478462 2026-03-18

CLOVER-2

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
30 enrolled
CNSGenitourinaryLymphoidSarcoma

Diffuse Intrinsic Pontine Glioma, Ependymoma, Glioblastoma, Glioma, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Sarcoma, Synovial, Neuroectodermal Tumors, Primitive, Neoplasms, Neuroepithelial, Gliosarcoma, Rhabdoid Tumor, Desmoplastic Small Round Cell Tumor

NCT05610891 2026-03-18

Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Cellectar Biosciences, Inc.

Phase 1 Active not recruiting
50 enrolled
CNS

Glioma

NCT01778088 2014-02-25

Open-Label Study of I-131-CLR1404 in Subjects With Recurrent Glioma

Cellectar Biosciences, Inc.

Phase 2 Withdrawn
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡